160 related articles for article (PubMed ID: 15473023)
1. Cetuximab in colon cancer.
Martin MJ
N Engl J Med; 2004 Oct; 351(15):1575-6; author reply 1575-6. PubMed ID: 15473023
[No Abstract] [Full Text] [Related]
2. The price tag on progress--chemotherapy for colorectal cancer.
Schrag D
N Engl J Med; 2004 Jul; 351(4):317-9. PubMed ID: 15269308
[No Abstract] [Full Text] [Related]
3. Cetuximab in colon cancer.
Costa AF; Sander GB; Picon PD
N Engl J Med; 2004 Oct; 351(15):1575-6; author reply 1575-6. PubMed ID: 15473024
[No Abstract] [Full Text] [Related]
4. New treatment options for colorectal cancer.
Erlichman C; Sargent DJ
N Engl J Med; 2004 Jul; 351(4):391-2. PubMed ID: 15269321
[No Abstract] [Full Text] [Related]
5. Cetuximab in the treatment of metastatic colorectal cancer: a model-based cost-effectiveness analysis.
Norum J
J Chemother; 2006 Oct; 18(5):532-7. PubMed ID: 17127231
[TBL] [Abstract][Full Text] [Related]
6. Considering Efficacy and Cost, Where Does Ramucirumab Fit in the Management of Metastatic Colorectal Cancer?
Goldstein DA; El-Rayes BF
Oncologist; 2015 Sep; 20(9):981-2. PubMed ID: 26265225
[TBL] [Abstract][Full Text] [Related]
7. Cetuximab as First-line Treatment for Metastatic Colorectal Cancer: Caution With Interpretation of Cost-Effectiveness Results Toward Medical Decision Making.
Franken MD; Koopman M; van Oijen MG
Am J Clin Oncol; 2016 Apr; 39(2):214. PubMed ID: 26999056
[No Abstract] [Full Text] [Related]
8. NICE guidance on cetuximab, bevacizumab, and panitumumab for treatment of metastatic colorectal cancer after first-line chemotherapy.
Rinaldi F; George E; Adler AI
Lancet Oncol; 2012 Mar; 13(3):233-4. PubMed ID: 22489288
[No Abstract] [Full Text] [Related]
9. Cost-effectiveness of cetuximab in combination with irinotecan compared with current care in metastatic colorectal cancer after failure on irinotecan--a Belgian analysis.
Annemans L; Van Cutsem E; Humblet Y; Van Laethem JL; Bleiberg H
Acta Clin Belg; 2007; 62(6):419-25. PubMed ID: 18351186
[TBL] [Abstract][Full Text] [Related]
10. New combinations in metastatic colorectal cancer: what are our expectations?
Hurwitz H
Oncologist; 2005 May; 10(5):320-2. PubMed ID: 15851788
[No Abstract] [Full Text] [Related]
11. [Utilizing synergism].
Krankenpfl J; 2005; 43(4-6):145. PubMed ID: 16171088
[No Abstract] [Full Text] [Related]
12. New issues on cetuximab mechanism of action in epidermal growth factor receptor-negative colorectal cancer: the role of vascular endothelial growth factor.
Vincenzi B; Santini D; Tonini G
J Clin Oncol; 2006 Apr; 24(12):1957; author reply 1957-8. PubMed ID: 16622275
[No Abstract] [Full Text] [Related]
13. Can the addition of cetuximab to irinotecan improve outcome in colorectal cancer?
Saltz LB
Nat Clin Pract Oncol; 2005 Jan; 2(1):20-1. PubMed ID: 16264850
[No Abstract] [Full Text] [Related]
14. ERBITUX as a single agent and in combination in colorectal carcinoma.
Expert Rev Anticancer Ther; 2002 Jun; 2(3):242. PubMed ID: 12113039
[No Abstract] [Full Text] [Related]
15. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.
Cunningham D; Humblet Y; Siena S; Khayat D; Bleiberg H; Santoro A; Bets D; Mueser M; Harstrick A; Verslype C; Chau I; Van Cutsem E
N Engl J Med; 2004 Jul; 351(4):337-45. PubMed ID: 15269313
[TBL] [Abstract][Full Text] [Related]
16. [Application of monoclonal antibody in combination with irinotecan in the treatment of colorectal cancer].
Li J
Zhonghua Zhong Liu Za Zhi; 2006 Oct; 28(10):796-7. PubMed ID: 17366800
[No Abstract] [Full Text] [Related]
17. [Progress of chemotherapy in colorectal cancer].
Komatsu Y
Gan To Kagaku Ryoho; 2007 Nov; 34(11):1771-6. PubMed ID: 18064761
[No Abstract] [Full Text] [Related]
18. Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting.
Asseburg C; Frank M; Köhne CH; Hartmann JT; Griebsch I; Mohr A; Osowski U; Schulten J; Mittendorf T
Clin Ther; 2011 Apr; 33(4):482-97. PubMed ID: 21635994
[TBL] [Abstract][Full Text] [Related]
19. [Our experience of the treatment with cetuximab for unresectable advanced colorectal cancer].
Yokomizo H; Yoshimatsu K; Osawa G; Matsumoto A; Otani T; Yano Y; Itagaki H; Fujimoto T; Umehara A; Ogawa K
Gan To Kagaku Ryoho; 2010 Nov; 37(12):2249-51. PubMed ID: 21224537
[TBL] [Abstract][Full Text] [Related]
20. Bevacizumab in colorectal cancer.
Sharieff W
N Engl J Med; 2004 Oct; 351(16):1690-1; author reply 1690-1. PubMed ID: 15490497
[No Abstract] [Full Text] [Related]
[Next] [New Search]